Sumitomo, Otsuka Both Stand To Gain From CNS Partnership

 
• By Alaric DeArment

Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.

Schizophrenia
Sumitomo and Otsuka have entered a deal of up to $890m centered on psychiatric drugs • Source: Shutterstock

More from Deals

More from Business